These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 32212489)
41. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Catalona WJ; Southwick PC; Slawin KM; Partin AW; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Loveland KG; Bray KR Urology; 2000 Aug; 56(2):255-60. PubMed ID: 10925089 [TBL] [Abstract][Full Text] [Related]
42. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340 [TBL] [Abstract][Full Text] [Related]
43. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715 [TBL] [Abstract][Full Text] [Related]
44. Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. Fu Q; Moul JW; Bañez L; Sun L; Mouraviev V; Xie D; Polascik TJ Med Oncol; 2013 Mar; 30(1):326. PubMed ID: 23263824 [TBL] [Abstract][Full Text] [Related]
45. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer]. Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321 [TBL] [Abstract][Full Text] [Related]
46. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance. Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819 [TBL] [Abstract][Full Text] [Related]
47. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ; J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788 [TBL] [Abstract][Full Text] [Related]
48. Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium. Soenens C; Dekuyper P; De Coster G; Van Damme N; Van Eycken E; Quackels T; Roumeguère T; Van Cleynenbreugel B; Joniau S; Ameye F; Pathol Oncol Res; 2020 Oct; 26(4):2605-2612. PubMed ID: 32632897 [TBL] [Abstract][Full Text] [Related]
49. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature. Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026 [TBL] [Abstract][Full Text] [Related]
50. Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer? Kim SJ; Jeong TY; Yoo DS; Park J; Cho S; Kang SH; Lee SH; Jeon SH; Lee TY; Park SY Yonsei Med J; 2015 Nov; 56(6):1492-6. PubMed ID: 26446628 [TBL] [Abstract][Full Text] [Related]
51. Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy. Friedersdorff F; Groß B; Maxeiner A; Jung K; Miller K; Stephan C; Busch J; Kilic E Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245570 [TBL] [Abstract][Full Text] [Related]
52. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer. Chaoying L; Chao M; Xiangrui Y; Yingjian H; Gang Z; Yunhan R; Yu G Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):391-398. PubMed ID: 35113414 [TBL] [Abstract][Full Text] [Related]
53. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Kupelian PA; Katcher J; Levin HS; Klein EA Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811 [TBL] [Abstract][Full Text] [Related]
54. Correlation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results. Pourmand G; Gooran S; Hossieni SR; Guitynavard F; Safavi M; Sharifi A; Mokhtari E Acta Med Iran; 2017 Apr; 55(4):249-253. PubMed ID: 28532136 [TBL] [Abstract][Full Text] [Related]
55. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer. Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896 [TBL] [Abstract][Full Text] [Related]
56. The impact of prostate-specific antigen, its density and the Gleason score in the prediction of extracapsular disease in prostate carcinoma. Akdaş A; Tarcan T; Türkeri L; Biren T; Küllü S; Ilker Y Eur Urol; 1997; 31(3):311-6. PubMed ID: 9129922 [TBL] [Abstract][Full Text] [Related]
57. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients. Caster JM; Falchook AD; Hendrix LH; Chen RC Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621 [TBL] [Abstract][Full Text] [Related]
58. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
59. Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels. Schmid HP; Ravery V; Billebaud T; Toublanc M; Boccon-Gibod LA; Hermieu JF; Delmas V; Boccon-Gibod L Urology; 1996 May; 47(5):699-703. PubMed ID: 8650868 [TBL] [Abstract][Full Text] [Related]
60. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]